CompletedNCT04599855
A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression
Medication studyAges 18+United States
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- Birmingham and 53 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: November 4, 2020
- Recruitment status
- Completed
- Enrollment listed in the registry
- 477
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT04599855
- Official title
Show the full official title
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression
Recruitment & locations
CompletedBirmingham · Huntsville · Little Rock
44 more locations
- Glendale
- Los Angeles
- Oakland
- Redlands
- San Diego
- San Francisco
- Santa Ana
- Santee
- Farmington
- Hallandale
- Lakeland
- Orlando
- Tampa
- West Palm Beach
- Atlanta
- Marietta
- Chicago
- Joliet
- Lincolnwood
- Skokie
- Wichita
- Baltimore
- Gaithersburg
- Boston
- Watertown
- Worcester
- Ann Arbor
- Rochester Hills
- Saint Charles
- New York
- Stony Brook
- Columbus
- Dayton
- Oklahoma City
- Allentown
- Philadelphia
- Providence
- Austin
- Dallas
- Houston
- Richardson
- The Woodlands
- Wichita Falls
- Charlottesville
Questions about this study
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Did this study involve medication?
Yes. The study involved medication, including Esketamine 56 mg, Esketamine 84 mg and Placebo.
Who was this study for?
Listed age limits: from 18 years.
Want to find a study that may fit you better?
Explore HopeStage studies by mental health topic and refine the results to suit your situation.
Find a study that may fit me